In August 2014, privately held German company Orgentec Diagnostika GMBH -- majority owned by PE firm Water Street Healthcare Partners; ELISA, blot, and immunofluorescence testing -- acquired fellow diagnostics maker, publicly traded Corgenix Medical Corporation. Corgenix is involved in development of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood based test for aspirin effect. Selling over 50 diagnostic products through a global distribution network, Corgenix Medical Corporation's work organizes primarily around in vitro diagnostic (IVD) products for use in disease detection and diagnosis in North America and internationally. The firm provides ELISA tests; vascular disease products, such as antiphospholipid antibody testing products; and products that are used in the diagnosis of bleeding and clotting disorders, including von Willebrandâs disease (hemophilia B). The company also provides the AspirinWorks test kit, a urine test that measures aspirin dosage; and liver disease products. In addition, it offers contract manufacturing services to other diagnostic and life science companies, as well as contract product development services to strategic partners and alliances; and purchases and resells IVD products, instruments, instrument systems, and various reagents and supplies. The company manufactures and sells approximately 50 diagnostic products to hospitals, clinical testing laboratories, universities, biotechnology and pharmaceutical companies, and research institutions through a network of sales representatives, independent distributors, and private label agreements. Corgenix Medical Corporation has a strategic collaboration with Tulane University, and other industry and academic partners to develop a group of products to detect viruses identified as potential bio-terrorism agents.
